GB-115 & CCK analoguesГБ-115
What is it?
A synthetic CCK-4-related dipeptide mimetic with animal studies and early human anxiety reports; its analogue library belongs on a shared research card.
Research context
A synthetic CCK-4-related dipeptide mimetic with animal studies and early human anxiety reports; its analogue library belongs on a shared research card.
What the studies found
observational · 2019
31 adults with generalized anxiety disorder
A 31-patient, 21-day GAD pilot reported improvements in anxiety and selected cognitive measures. The abstract does not establish randomized blinded control or superiority to standard treatments.
Limit: Uncontrolled pilot evidence; expectancy and repeated-testing effects remain possible.
[Results of a clinical study of a new anxiolytic, a blocker of central cholecystokinin receptors]. ↗animal · 2013
Rodents; open-field and elevated-plus-maze experiments
Oral GB-115 changed anxiety-related behavior in rodents, with effects depending on strain and stress-response phenotype.
Limit: Preclinical findings do not establish human benefit or safety.
Anxiolytic activity of dipeptide GB-115 after oral administration. ↗animal · 2012
Rats and BALB/c and C57Bl/6 mice
GB-115 countered some CCK-4-induced behavioral responses but not yohimbine-induced anxiety in C57Bl/6 mice, indicating model-dependent effects rather than universal anxiolysis.
Limit: Preclinical findings do not establish human benefit or safety.
Role of the cholecystokinin system in anxiolytic activity of dipeptide GB-115. ↗Selected findings, not a systematic review or a treatment recommendation. Combination and related-preparation results cannot be attributed to this compound alone. See each source for access status and remaining limitations.
- Working classification
- Peptide research family
- Research collection
- Neuropeptide research · editorial grouping
- Institutional provenance
- Not established for this compound record
- Last evidence review
- Full evidence review pending; source-check scope appears with each publication below.
What do we know?
- Human research
- —31-patient pilot and possibly overlapping 25-patient conference analysis
- Study methods
- —Member-specific studies; patents and archival leads identified separately
- Independent replication
- —Independent replication not established by the records collected here
- Source access
- —Primary abstracts, selected full texts, patents and explicit retrieval targets
- Safety evidence
- —Cell and animal effects do not establish human safety; analogues may differ
These are independent review fields, not a rating. Missing evidence in this starter does not mean no research exists.
Inside this research family
Grouping supports navigation. It does not imply equivalent composition, mechanisms, effectiveness or safety.
| Member | Identity | What the source supports |
|---|---|---|
| GB-115 | CCK-4 retroanalogue | Model-dependent rodent findings and a 31-patient GAD pilot. Role of the cholecystokinin system in anxiolytic activity of dipeptide GB-115. ↗ Anxiolytic activity of dipeptide GB-115 after oral administration. ↗ [Results of a clinical study of a new anxiolytic, a blocker of central cholecystokinin receptors]. ↗ |
| 25-patient analysis | Conference report | Possible overlap with the earlier pilot; no independent-replication claim. Clinical effects of GB-115 in patients with Generalized Anxiety Disorder ↗ |
| GB-101 / stereochemical variants | Related medicinal-chemistry leads | Original member-specific studies and receptor assignments remain to be reviewed. Original-source recovery pending |
Interpretation and open questions
Human pilot findings do not establish superiority to standard therapies.
CCK receptor subtype claims, affinity and behavioral mechanism should be examined separately; a design origin alone does not settle the receptor target.
Linked sources
Explore the research map and unresolved leads ↗
[Results of a clinical study of a new anxiolytic, a blocker of central cholecystokinin receptors].
Neznamov GG, Dorofeeva OA, Metlina MV, Syunyakov TS, Minaev SV, Ivashkina NY, Martyanov VA, Seredenin SB · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
A 31-patient, 21-day GAD pilot reported improvements in anxiety and selected cognitive measures. The abstract does not establish randomized blinded control or superiority to standard treatments.
- Population / setting
- 31 adults with generalized anxiety disorder
- What was checked
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Limitations & review scope
- Uncontrolled pilot evidence; expectancy and repeated-testing effects remain possible.
- Later 25-patient conference analyses may overlap and are not counted as independent replication.
Source checked 2026-10-05. This is a source-linked record, not a completed evidence review.
Anxiolytic activity of dipeptide GB-115 after oral administration.
Kolik LG, Konstantinopolsky MA, Ryibina IV, Povarnina PY, Gudasheva TA, Seredenin SB · Bulletin of experimental biology and medicine
Oral GB-115 changed anxiety-related behavior in rodents, with effects depending on strain and stress-response phenotype.
- Population / setting
- Rodents; open-field and elevated-plus-maze experiments
- What was checked
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Limitations & review scope
- Preclinical findings do not establish human benefit or safety.
- Indexed abstract reviewed; full methods and independent replication require appraisal.
Source checked 2026-10-05. This is a source-linked record, not a completed evidence review.
Role of the cholecystokinin system in anxiolytic activity of dipeptide GB-115.
Kolik LG, Gudasheva TA, Seredenin SB · Bulletin of experimental biology and medicine
GB-115 countered some CCK-4-induced behavioral responses but not yohimbine-induced anxiety in C57Bl/6 mice, indicating model-dependent effects rather than universal anxiolysis.
- Population / setting
- Rats and BALB/c and C57Bl/6 mice
- What was checked
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Limitations & review scope
- Preclinical findings do not establish human benefit or safety.
- Indexed abstract reviewed; full methods and independent replication require appraisal.
Source checked 2026-10-05. This is a source-linked record, not a completed evidence review.
Novel Technologies for Dipeptide Drugs Design and their Implantation.
Gudasheva TA, Ostrovskaya RU, Seredenin SB · Current pharmaceutical design
The developers distinguish drug-inspired peptide design (Noopept and Dilept) from mimicking peptide/protein turns (GB-115 and GK-2). This is a historical design framework, not evidence of a shared clinical effect.
- Population / setting
- Developer account of medicinal-chemistry programs
- What was checked
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Limitations & review scope
- Developer review; claims require appraisal of each original study.
- A shared design method does not establish equivalent biology or clinical benefit.
Source checked 2026-10-05. This is a source-linked record, not a completed evidence review.
Clinical effects of GB-115 in patients with Generalized Anxiety Disorder
· Conference abstract
· European Psychiatry. 65(Suppl 1):S388
A conference post-hoc analysis of 25 patients reported lower anxiety and fatigue scores over 21 days. Its relationship to the earlier pilot must be resolved before treating it as independent evidence.
- Population / setting
- 25 patients; uncontrolled conference report
- What was checked
- Selected original-source text checked; full methodological review pending.
Limitations & review scope
- Conference abstract, not a full clinical report.
- No placebo comparison; possible overlap with the 31-patient pilot.
Source checked 2026-10-05. This is a source-linked record, not a completed evidence review.